BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year High – Here’s What Happened

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) reached a new 52-week high on Monday . The stock traded as high as $25.80 and last traded at $25.4950, with a volume of 37788 shares traded. The stock had previously closed at $25.10.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BIOA shares. Needham & Company LLC started coverage on BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. BTIG Research began coverage on shares of BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Citigroup boosted their price objective on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Roth Capital started coverage on shares of BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price for the company. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs presently has an average rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Trading Down 1.8%

The company has a market cap of $1.08 billion, a P/E ratio of -10.17 and a beta of 0.61. The business has a 50 day moving average price of $18.98 and a 200-day moving average price of $18.51.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million during the quarter. On average, sell-side analysts expect that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Institutional Investors Weigh In On BioAge Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Nano Cap New Millennium Growth Fund L P bought a new position in BioAge Labs during the fourth quarter worth about $1,058,000. Y Intercept Hong Kong Ltd bought a new stake in BioAge Labs in the first quarter valued at approximately $3,521,000. Sei Investments Co. bought a new stake in BioAge Labs in the first quarter valued at approximately $1,091,000. Renaissance Technologies LLC lifted its position in shares of BioAge Labs by 653.2% in the first quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after buying an additional 120,188 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of BioAge Labs during the 1st quarter worth approximately $1,537,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.